Hotwire Global Communications Expands Its Global Tech Communications Leadership With New Hires and Client Wins
Hotwire, the global tech communications consultancy, is welcoming new leaders as the company continues further expansion of its capabilities and adds new, innovative brands to the client roster.
Hotwire is building on its strategic acquisition of McDonald Butler Associates to unlock new possibilities of growth and present clients with a more robust communications offering and access to new skills and services. This new level of communication has been designed to build brand reputation, strengthen stakeholder relationships and deliver revenue growth, igniting the entire marketing ecosystem and supporting CMOs in growing their businesses.
“Technology and innovation leaders are continuing to manage complexity and are seeking out solutions to support,” said Heather Kernahan, global CEO of Hotwire. “This year we took steps to narrow the gaps that exist between marketing and sales with new integrated offerings and strengthened our relationships with clients as they navigated major shifts in their business. We’re also working with some amazing new brands and deepening our expertise and leadership across key areas of the business.”
New Leaders Support Rapid Growth
Hotwire continues to add senior leaders in strategy, planning, digital and client consulting to its teams across the world. This past quarter key hires have been made in Germany, the U.K., and the U.S.
In Germany, Martin Opercan joined Hotwire as a Senior Director, Strategic Growth and will be responsible for client strategy and planning. Martin brings over 20 years of experience in marketing, communications and business development and most recently oversaw the Munich office for diffferent.
Rebecca Rhodes and Anastasia Pavolva recently joined the Hotwire U.K. team. Rebecca is Head of Planning and before joining Hotwire, ran her own consultancy, SuperHuman and also previously was Global Chief Creative Officer at Golin. Anastasia is a Strategy Director with experience working in global agencies such as Ogilvy and in brand management at Procter & Gamble.
In the U.S., two new Senior Vice Presidents will join the leadership and client services team. Andrea Holland has worked in tech comms across large global brands including Intuit, PayPal and LegalZoom as well as early stage B2C tech startups. Andrea is a PR instructor and author for LinkedIn Learning and most recently ran her own consultancy, DialedPR. She also founded the nation's #1 jobs site for PR professionals looking for remote work, RemotePRJobs. Jessica Heagerty comes to Hotwire from Dell Technologies where she held roles in Analyst Relations and Field Marketing. Jessica started her career working for global brands in leading communications agencies.
Tech Innovators Choose Hotwire to Ignite New Opportunities
As Hotwire continues to provide a new level of communication expertise helping companies build brand reputation, strengthen stakeholder relationships and deliver revenue growth, it’s igniting the entire marketing ecosystem and supporting ambitious companies in growing their businesses.
New clients include fast growing and global innovators who selected Hotwire for its technology and innovation expertise and consultancy approach. Most recently, Hotwire signed on Aircall, BAM Karaoke, Bright Machines, Cobrainer, QA, Rocket App and Splashtop.
Award Winning Client Work and Global Recognition
Hotwire and individuals across the agency continue to gain recognition for leadership and impactful client work. Ludi Garcia, Managing Director of Hotwire Spain, was recently recognized as the #1 most admired communications professional in Spain by SCOPEN and Hotwire was named Best Comms PR consultancy, as voted for by PR professionals working in agencies.
Hotwire’s work on Zoomtopia, Zoom’s annual conference, received Honorable Mention for Ragan Comms' Media Relations Award for Virtual Event and is shortlisted in the PR report awards.
The company was also recently named in the Propel 100 list as one of the most influential PR agencies in the world in 2021.
Expanding Partnerships in The Tech Ecosystem
Hotwire is partnering with organizations across the world who are working to advance technology innovation and the leaders pushing the industry forward. The company is now a member of Tech UK, which brings together people, companies and organizations to realize the positive outcomes of what digital technology can achieve.
Hotwire is also a sponsor for Get On Board, which is a week of education and training to prepare women leaders for Board positions. The company is also a sponsor of Alley to the Valley, a community of accomplished women who fast-track business opportunities for each other. Hotwire supports board readiness and women in leadership with Executive Thought Leadership and Media Training and Speaker Readiness services.
To learn more about Hotwire, visit https://www.hotwireglobal.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005562/en/
Contact information
Hotwire
Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom